Protection by epicoprostanol against hyperglycemia and insulitis in normal and diabetic rats

Journal of Ethnopharmacology

Volumn 50, Issue 2, 1996, Pages 85-90

  Taha, S A ^a   Raza, M ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Epicoprostanol; Hypoglycemia; Insulin; Insulitis

Indexed keywords

AMBERGRIS; EPICOPROSTEROL; GLUCOSE; INSULIN; UNCLASSIFIED DRUG;

ALLOXAN DIABETES MELLITUS; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULITIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NONHUMAN; RAT;

EID: 0030060035     PISSN: 03788741     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-8741(95)01333-4     Document Type: Article

References (30)

1. Al-Gozech, K. (1981) Prophet Medicine, 2nd edn., p. 340, Al-Resala Publishers, Syria.
2. Arison, R.N., Ciaccio, E.I., Glitzer, M.S., Casaro, J.A. and Pruss, M.P. (1967) Light and electron microscopy of lesions in rats rendered diabetic with streptozotocin. Diabetes 16, 51-56.
3. Arison, R.N. and Fendale, E.L. (1967) Induction of renal tumors by streptozotocin in rats. Nature 204, 1254-1255.
4. Benton, W. (1963) Encyclopedia Britannica, Vol.1, p. 718, Encyclopaedia Britannica, Inc. Chicago.
5. Bonnevie-Nielsen, V., Stoffes, M.W. and Lernmark, A. (1981) A major loss in islet mass and β-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin. Diabetes 30, 424-429.
6. Cambie, R.C. (1967) Perfumes related to ambergris. Chemistry and Industry in New Zealand 3, 4-8.
7. Dannenfeldt, K.H. (1982) Ambergris: The search for its origin. Isis 73, 382-397.
8. Einhorn, D. (1992) Practical management of the patient with type II (noninsulin dependent) diabetes. Modern Medicine of the Middle East 9(3), 20-32.
9. Epstein, WL. (1975) Report to RIFM Fenarolis Handbook of Flavour Ingredients, Furia T.E. and Ballauca N. (eds.), 2nd edn., vol. 1, p. 273, CRC Press Cleaveland.
10. Guillem, J.G., Clemens, M.G., Chaudhry, I.H., McDermott, P.H. and Baue, A.E. (1982) Hepatic gluconeogenetic capability in sepsis is depressed before changes in oxidative capability. Journal of Trauma 22, 723.
11. Helgason, T. and Jonasson, M.R. (1981) Evidence for a food additive as cause of ketosis-prone diabetes. Lancet 2, 716-720.
12. Junod, A., Lamber, A.E., Orci, L., Pidet, R., Gonet, A.E. and Reynold, A.E. (1967) Studies of the diabetogenic action of streptozotocin. Proceedings of the Society of Experimental Biologist 126, 201-205.
13. Karam, J.H., Lewitt, P.H., Young, C.W., Nowlain, R.E., Frankel, B.J., Fujiya, H., Fredman, R.Z. and Groodsky, G.M. (1980) Insulinopenic diabetes after rodenticide (vacor) ingestion: A unique model of acquired diabetes in man. Diabetes 29, 971-978.
14. Lawrence, B.M. (1983) Progress in essential oils. Perfumer and Flavorist 8, 61-66.
15. Merck Index (1968) An Encyclopedia of Chemicals and Drugs, 8th edn. p. 49, Merck and Co. Inc., Rahway.
16. Mookherjee, B.D. and Patel, R.R. (1977) Isolation and identification of volatile constituents of tincture ambergris. Paper No. 137, 7th International Congress of Essential Oils, Kyoto, Japan, pp. 479-81.
17. Ohloff, G. (1982) In: Ernst T. Theimer (Ed.), The Fragrance of Ambergris, Academic Press, New York, pp. 535-573.
18. Rossini, A.A., Williams, R.M., Appel, M.C. and Like, A.A. (1978) Complete protection from low-dose streptozotocin-induced diabetes in mice. Nature 276, 182-184.
19. Taha, S.A. (1989) General pharmacological screening on ambergris extract. Pakistan Journal of Pharmacology 6, 75-88.
20. Taha, S.A. and Rashid, S. (1990) Preliminary investigations on cardiovascular profile of ambrein. Pakistan Journal of Pharmacology 7, 95-100.
21. Taha, S.A. (1994) Role of prostaglandin E2 in the antiinflammatory and antinociceptive activities of ambrein. Medical Science Research, 22(2), 97-98.
22. Taha, S.A. (1992) Studies on the mode of action of ambrein as a new antinociceptive compound. Japanese Journal of Pharmacology 60, 67-71.
23. Taha, S.A. and Ginawi, O.T. (1993) Ambrein, the major constituent of ambergris, inhibits oedema responses to carrageenin and serotonin in the rat paw. Bulletin of the Faculty of Pharmacy, Cairo University, 31(1), 113-114.
24. Taha, S.A. and Ginawi, O.T. (1995) Effect of ambrein on smooth muscle responses to various agonists. Saudi Pharmaceutical Journal (accepted for publication).
25. Taha, S.A. and Islam, M.W. (1994) Effect of ambrein, a major constituent of ambergris, on some hormonal levels in normal Wistar rats. Saudi Pharmaceutical Journal 2(4), 174-178.
26. Taha, S.A. (1991) Effect of ambrein on blood glucose levels of rats. Journal of Ethnopharmacology 35, 145-148.
27. Taha, S.A., Raza, M., Gader, A.G.M.A. and Hafeez, M.A. (1995a) A study of ambrein treatment for the evaluation of change in plasma biochemical parameters in rats. Japanese Journal of Pharmacology 67, 205-209.
28. Taha, S.A., El-Olemy, M.M. and Raza, M. (1995b) Evaluation of epicoprostanol: A major sterol of ambergris for antiinflammatory and antipyretic activities. In: Souvenir Abstracts, First National Conference on Pharmacology and Therapeutics, University of Karachi, Karachi, Pakistan (January 21-22) 1995, pp. 54.
29. Taha, S.A. and Ginawi, O.T. (1995a) The analgesic activity of epicoprostanol, the major sterol of ambergris. In: Souvenir Abstracts, First National Conference on Pharmacology and Therapeutics, University of Karachi, Karachi, Pakistan (January 21-22) 1995, pp. 53.
30. Toniolo, A., Onodera, T., Yoon, J.W. and Notkins, A.L. (1980) Introduction of diabetes by cumulative environmetal insults from viruses and chemicals. Nature 288, 383-385.